Celyad Reports First Half 2015 Financial Results and Operational Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. RTX
6. COF
7. SMCI
8. GOOGL
9. TSLA
10. CRWV

Go back to Celyad Reports First Half 2015 Financial Results and Operational Progress

UBS Cuts Price Target on Celyad SA (CYAD) to $79 Following 1H15

August 26, 2015 8:50 AM EDT

UBS maintained a Buy rating on Celyad SA (NASDAQ: CYAD), and cut the price target to $79.00 (from $82.00), following the company's 1H15 The key focus for analyst Andrew Peters is on timelines and the path forward for both the CHART program in heart failure as well as the NKG2D-based CAR-T therapy currently in phase-1 trials. Management confirmed that CHART-1 continues on-track, with top-line data... More